id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-N-0237-0051,FDA,FDA-2006-N-0237,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Charging for Investigational Drugs",Notice,Notice of Approval,2011-02-25T05:00:00Z,2011,2,2011-02-25T05:00:00Z,,2016-02-12T14:52:37Z,2011-04217,0,0,0900006480bf7af9
FDA-2006-N-0237-0050,FDA,FDA-2006-N-0237,Reference re OMB Review Charging for IND Treatment Use Final Rule,Other,References (internal) (REF),2009-08-18T04:00:00Z,2009,8,2009-08-18T04:00:00Z,,2016-02-18T16:24:04Z,,0,0,0900006480a0b971
FDA-2006-N-0237-0049,FDA,FDA-2006-N-0237,Notice of Final Rule re Charging for Investigational Drugs Under an Investigational New Drug Application,Rule,Final Rule,2009-08-13T04:00:00Z,2009,8,2009-08-13T04:00:00Z,,2016-02-09T20:59:52Z,E9-19004,0,0,0900006480a08453
FDA-2006-N-0237-0043,FDA,FDA-2006-N-0237,Request for Extension from Pendergast Consulting,Other,Request for Extension,2008-12-11T05:00:00Z,2008,12,2008-12-11T05:00:00Z,,2016-02-05T18:52:44Z,,0,0,0900006480456b9a
FDA-2006-N-0237-0044,FDA,FDA-2006-N-0237,Attachment A Comments in Response to the Food and Drug Administration Notices of Proposed Rulemaking Response of America's Health Insurance Plans re Comment from America's Health Insurance Plans (AHIP),Supporting & Related Material,Background Material,2008-12-11T05:00:00Z,2008,12,,,2016-02-05T18:31:42Z,,0,0,0900006480456c00
FDA-2006-N-0237-0042,FDA,FDA-2006-N-0237,Request for Extension from Public Citizen,Other,Request for Extension,2008-12-11T05:00:00Z,2008,12,2008-12-11T05:00:00Z,,2016-02-09T19:04:57Z,,0,0,0900006480456b95
FDA-2006-N-0237-0013,FDA,FDA-2006-N-0237,Reference 1 OMB Review re Comment from HF-26,Supporting & Related Material,Reference (internal unless indicated),2008-10-10T04:00:00Z,2008,10,,,2016-02-05T20:28:17Z,,0,0,0900006480456b67
FDA-2006-N-0237-0012,FDA,FDA-2006-N-0237,Cancer Leadership Council (CLC) to the FDA - Letter,Other,LET-Letter,2008-10-10T04:00:00Z,2008,10,2008-10-10T04:00:00Z,,2013-07-28T01:56:37Z,,0,0,09000064807444fd
FDA-2006-N-0237-0006,FDA,FDA-2006-N-0237,Comment from California Department of Health Services,Supporting & Related Material,Background Material,2007-03-19T04:00:00Z,2007,3,,,2016-02-08T20:06:02Z,,0,0,0900006480456bb7
FDA-2006-N-0237-0003,FDA,FDA-2006-N-0237,Memorandum re Office of Policy and Planning to the Division of Dockets Management - [Request for Extension of Comment Period],Other,Memorandum,2007-03-13T04:00:00Z,2007,3,,,2016-02-05T18:47:35Z,,0,0,0900006480456b9c
FDA-2006-N-0237-0001,FDA,FDA-2006-N-0237,Notice of Proposed Rulemaking re Charging for Investigational Drugs,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2006-12-14T05:00:00Z,2006,12,2006-12-14T05:00:00Z,2007-03-21T03:59:59Z,2016-02-12T22:00:43Z,,0,0,0900006480456b5d